DEF: Liminatus Pharma Annual Meeting: Director Election & Stock Split

Liminatus Pharma, Inc. is holding its 2026 Annual Meeting of Stockholders on August 3, 2026, to elect directors, ratify auditors, and approve a reverse stock split.

Summary

• Liminatus Pharma, Inc. has scheduled its 2026 Annual Meeting of Stockholders for August 3, 2026, at 10:30 a.m. Pacific time.
• The meeting will be held at the company's offices in Fullerton, California, and virtually.
• Key agenda items include the election of two directors, Nicholas Fernandez and Dr. Ji Yeon Baek, for three-year terms.
• Stockholders will also vote on ratifying the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• A significant proposal is the authorization for the Board of Directors to approve a reverse stock split of the Company's common stock at a ratio of up to 1-for-50.
• This reverse stock split is primarily intended to meet the minimum bid price requirements for listing on the Nasdaq Stock Market or another national securities exchange.
• The meeting will also address amendments to the company's certificate of incorporation to reflect the reverse stock split.
• Stockholders of record as of July 2, 2026, are entitled to vote.
• The company's Board of Directors recommends voting FOR all proposals.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to the company's non-compliance with Nasdaq listing rules, necessitating a reverse stock split, which can be a double-edged sword for investor perception.

Positives

• The company is proactively addressing potential Nasdaq listing issues through a proposed reverse stock split, aiming to maintain market access.
• The proposed reverse stock split, if approved, could increase the per-share price, potentially making the stock more attractive to a broader range of investors.
• Key independent directors and management are nominated for re-election, indicating a degree of continuity.
• The company has a robust audit committee structure with a designated financial expert, Nicholas Fernandez.
• The company has a comprehensive 2025 Omnibus Equity Incentive Plan designed to attract, motivate, and retain talent.

Negatives

• The company received a notice from Nasdaq on January 15, 2026, indicating non-compliance with the minimum bid price rule ($1 per share) and has until July 14, 2026, to regain compliance.
• A reverse stock split can sometimes be viewed negatively by the market and may not guarantee a sustained increase in share price or improved liquidity.
• The reverse stock split may lead to an increase in the number of stockholders holding 'odd lots' (less than 100 shares), potentially increasing transaction costs for these stockholders.
• The company's Board of Directors held no meetings during fiscal year 2025, which could raise governance concerns.
• The company has a significant number of shares of Series A Preferred Stock that are not convertible into common stock without further stockholder approval, creating a potential hurdle for future conversions.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price rule by July 14, 2026, could result in delisting from Nasdaq, potentially leading to trading on less efficient over-the-counter markets.
• The reverse stock split may not result in a sustained increase in the stock price or may decrease liquidity.
• The reverse stock split could lead to a decrease in the company's overall market capitalization if the per-share price does not increase proportionally.
• Stockholders holding odd lots after the reverse stock split may face higher transaction costs.
• The company's business combination and related transactions involved complex financial arrangements, including significant intercompany loans and potential future obligations.
• The company's ability to raise capital in the future may be impacted by its listing status and stock performance.

Future Outlook

The primary forward-looking aspect is the proposed reverse stock split, aimed at meeting Nasdaq's minimum bid price requirement. The company believes this action, along with potential future capital raises, is crucial for its continued listing and attractiveness to investors. The success of these initiatives is contingent on stockholder approval and market conditions.

Management Comments

• The Board believes that effecting the Reverse Stock Split is in the Company's and our stockholders' best interests.
• Our Board strongly believes that the Reverse Stock Split is necessary to maintain our listing on Nasdaq or another national securities exchange.
• The leadership structure combining CEO and Chairman roles provides unified direction and facilitates efficient decision-making.
• We believe these provisions in the Company's Certificate of Incorporation and bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers.

Industry Context

StockSavvy.ai notes that maintaining a listing on major exchanges like Nasdaq is critical for pharmaceutical companies seeking access to capital and investor confidence. Companies often resort to reverse stock splits to meet minimum bid price requirements, a common challenge for smaller or growth-stage biopharma firms facing market volatility or developmental setbacks. Competitors in the biotech space frequently face similar listing pressures.

Comparison to Industry Standards

• The proposed reverse stock split ratio of up to 1-for-50 is within the typical range seen for companies needing to boost their share price to meet exchange listing requirements.
• The company's audit committee structure, with a designated financial expert and independent members, aligns with best practices for corporate governance in the pharmaceutical industry.
• The 2025 Omnibus Equity Incentive Plan, reserving 2,000,000 shares, is a standard mechanism for incentivizing employees and directors in the sector, though the exact impact depends on grant sizes and vesting schedules.
• The company's reliance on a single audit firm (WithumSmith+Brown, PC) for multiple years is common, but industry best practices often suggest periodic review or rotation of auditors to ensure continued independence and fresh perspectives.

Corporate Governance

Related Party Transactions

• Chris Kim, CEO and Director, is also the CEO and controlling member of Valetudo Therapeutics LLC, which received 3,448,926 shares of common stock and 48,975.1074 shares of Series A Preferred Stock in the acquisition of InnocsAI LLC.
• Beom K. Choi, CTO, is also CEO of Samda Biolab Co., Ltd., which received 3,426,548 shares of common stock and 48,657.3452 shares of Series A Preferred Stock in the acquisition of InnocsAI LLC.
• Valetudo Therapeutics LLC (beneficially owned by Chris Kim) holds voting power over shares held by Ewon Comfortech Co., Ltd. through a voting agreement.
• Iris Acquisition Corp had an administrative support agreement with Arrow Capital Management LLC, incurring $200,000 in fees in 2024.
• Hana Immunotherapeutics, LLC (an affiliate of Chris Kim) loaned approximately $1.216 million to Gaius Investment Partners to facilitate Gaius's acquisition of Columbass Limited.
• Liminatus provided unsecured promissory notes to Iris, with the principal amount increasing over time, reaching up to $5,000,000 by November 27, 2024. As of December 31, 2024, $3,668,500 was outstanding; this balance was $0 by December 31, 2025.
• The company issued 100 shares of common stock to Chris Kim for $10 in November 2022, with no consideration received as of March 31, 2025.

Stakeholder Impact

• Shareholders: The proposed reverse stock split could impact share price and liquidity. Failure to maintain Nasdaq listing would significantly affect share value and trading accessibility. Election of directors and auditor ratification are standard shareholder votes.
• Management: The reverse stock split is intended to benefit the company and its shareholders by maintaining exchange listing. Management compensation is detailed, with a 2025 Omnibus Equity Incentive Plan available.
• Creditors: The filing does not directly address impacts on creditors, but maintaining exchange listing and financial stability is generally beneficial for debt holders.
• Employees: The equity incentive plan may benefit employees through stock awards. The company's ability to maintain listing and potentially raise capital impacts job security and growth opportunities.

Next Steps

• Stockholders to vote on the election of directors, ratification of auditors, and approval of the reverse stock split and charter amendment at the Annual Meeting on August 3, 2026.
• If approved, the Board of Directors will determine the final ratio for the reverse stock split and effect the charter amendment.
• The company must regain compliance with Nasdaq's minimum bid price rule by July 14, 2026, or seek additional time.
• Stockholder proposals for the 2027 Annual Meeting must be submitted by March 15, 2027.

Key Dates

Recommendation

The filing indicates a critical need to address Nasdaq listing compliance via a reverse stock split, which carries inherent risks and market perception challenges. While the company is taking steps to maintain its listing, the underlying business performance and the success of the reverse split in boosting share price and liquidity are uncertain. Therefore, a 'hold' recommendation is appropriate pending further clarity on compliance and market reaction.

Keywords

Liminatus Pharma, Annual Meeting, Proxy Statement, DEF 14A, Reverse Stock Split, Nasdaq Listing, Director Election, Auditor Ratification, Corporate Governance, SEC Filing